Ideas to Action:

Independent research for global prosperity

Global Health Policy

CGD experts discuss such issues as health financing, drug resistance, clinical trials, vaccine development, HIV/AIDS, and health-related foreign assistance.

X

Global Health Policy

Feed

 

The Global Fund Opens Up

 

The Global Fund to Fight AIDS, TB and Malaria recently made it easier to find out where their money is going with the launch of a new, online grant portfolio portal.   This welcome and timely tool comes amid the Global Fund’s ambitious replenishment process that asks donors for $15 billion over the next three years to fight HIV/AIDS, TB and malaria – a considerable amount that totals twice the Fund’s average annual disbursements over the past decade.  So we’re pleased to see the Global Fund take such a significant step to show stakeholders how these investments are being spent and what they are achieving.   And as avid users of Global Fund data ourselves, we’re particularly pleased to see a few features of this new tool:

 

Meet the Global Health Family: A Cheat Sheet

This is a joint post with Rachel Silverman.

Through our Value for Money working group, we’ve spent much of the past year immersed in the world of global health funding agencies. With so many new agencies, particularly in the last quarter century (Figure 1), understanding the intricacies of the global health family can be daunting, even for the most devoted observers.

Is Health Insurance Good for Health?

The New England Journal of Medicine recently published the results of “the Oregon experiment” based on the 2008 US Medicaid program expansion in Oregon. The study is one of very few randomized control trials on publicly-subsidized health insurance that exists to guide health policy, and found what some commentators considered a disappointing result: while health care utilization increased and households were protected from financial hardship, expanding Medicaid coverage had “no significant impact on measured physical health outcomes over a 2-year period.”

From Audits to Results: A Needed Paradigm Shift in Health Aid

The World Bank’s Africa Health Forum: Finance & Capacity for Results during its 2013 Spring Meetings brought together ministers of finance and of health from 30 African countries in a unique opportunity for mutual listening between countries and partners. One recurring theme in forum and in the first panel was that results-based financing (RBF) – where financing is conditioned on achievement of results in health – is a key approach to driving value for money. In short: RBF = more money for more health. (You can watch the recorded ministerial discussion here.)

“Better Than Average” Is Not Good Enough: Accelerating Child Survival in India

Last week, the Government of India held a star-studded National Summit on child survival, “co-convened”* with USAID and UNICEF. The high-profile meeting featured politicians (the Minister of Health & Family Welfare, the US Ambassador to India), heavy-hitters in global child health (Bob Black, Zulfiqar Bhutta, Mickey Chopra, Geeta Rao Gupta) along with some Indian stars of child health (Vinod Paul, Abhay Bang, Yogesh Jain), and even a Bollywood actress/“child rights activist” Nandana Sen (daughter of Nobel Laureate and Professor Amartya Sen), to name a few.

Top 10 Posts of 2012 from CGD’s Global Health Policy Blog

It’s that magical time of the year when we bring you the top 10 most read entries on the CGD Global Health Policy Blog.  Together, these top posts had a total almost 20,000 unique page views. This year the blog asked for your feedback on evaluating the quality of health aid, addressed the debate over entities like the GHI and AMFm, and discussed everything from cash transfers to priority-setting.

The Future of AMFm: Realpolitik and Realistic Options (Part II)

This week the Global Fund Board will determine whether to “expand, accelerate, terminate or suspend the Affordable Medicines Facility – malaria (AMFm).” Ideally, the Board would make an evidence-based decision. However, both the sufficiency and the relevance of available technical evidence have been questioned (see here and here). The role of political and process evidence is also not very transparent. Below, we lay out our understanding of the potential options and the factors the Board should consider.

The Future of AMFm: Making Sense from All the Noise

This is a joint post with Heather Lanthorn.

The Global Fund Board’s decision over the Affordable Medicines Facility – malaria (AMFm) rapidly approaches, and tensions within the malaria community are acute. In her global health blog for The Guardian, Sarah Boseley characterizes the rift as one of

huge arguments and intense passions…[because] it is about the belief on one side that the private sector is the most effective way to get medicines to those who need them – and the certainty on the other side that bolstering the public sector to diagnose and treat people is a fairer and safer way to go. These are not just practical matters, but highly political.”

Pages

Tags